Diagnostic value of plasma p-tau181, NfL, and GFAP in a clinical setting cohort of prevalent neurodegenerative dementias.
Alpha-synuclein
Alzheimer disease
Corticobasal syndrome
FTLD
Frontotemporal dementia
Lewy bodies
Progressive supranuclear palsy
RT-QuIC
Tau
Journal
Alzheimer's research & therapy
ISSN: 1758-9193
Titre abrégé: Alzheimers Res Ther
Pays: England
ID NLM: 101511643
Informations de publication
Date de publication:
12 10 2022
12 10 2022
Historique:
received:
01
04
2022
accepted:
29
09
2022
entrez:
11
10
2022
pubmed:
12
10
2022
medline:
14
10
2022
Statut:
epublish
Résumé
Increasing evidence supports the use of plasma biomarkers of neurodegeneration and neuroinflammation to screen and diagnose patients with dementia. However, confirmatory studies are required to demonstrate their usefulness in the clinical setting. We evaluated plasma and cerebrospinal fluid (CSF) samples from consecutive patients with frontotemporal dementia (FTD) (n = 59), progressive supranuclear palsy (PSP) (n = 31), corticobasal syndrome (CBS) (n = 29), dementia with Lewy bodies (DLB) (n = 49), Alzheimer disease (AD) (n = 97), and suspected non-AD physiopathology (n = 51), as well as plasma samples from 60 healthy controls (HC). We measured neurofilament light chain (NfL), phospho-tau181 (p-tau181), and glial fibrillary acid protein (GFAP) using Simoa (all plasma biomarkers and CSF GFAP), CLEIA (CSF p-tau181), and ELISA (CSF NfL) assays. Additionally, we stratified patients according to the A/T/N classification scheme and the CSF α-synuclein real-time quaking-induced conversion assay (RT-QuIC) results. We found good correlations between CSF and plasma biomarkers for NfL (rho = 0.668, p < 0.001) and p-tau181 (rho = 0.619, p < 0.001). Plasma NfL was significantly higher in disease groups than in HC and showed a greater increase in FTD than in AD [44.9 (28.1-68.6) vs. 21.9 (17.0-27.9) pg/ml, p < 0.001]. Conversely, plasma p-tau181 and GFAP levels were significantly higher in AD than in FTD [3.2 (2.4-4.3) vs. 1.1 (0.7-1.6) pg/ml, p < 0.001; 404.7 (279.7-503.0) vs. 198.2 (143.9-316.8) pg/ml, p < 0.001]. GFAP also allowed discriminating disease groups from HC. In the distinction between FTD and AD, plasma p-tau181 showed better accuracy (AUC 0.964) than NfL (AUC 0.791) and GFAP (AUC 0.818). In DLB and CBS, CSF amyloid positive (A+) subjects had higher plasma p-tau181 and GFAP levels than A- individuals. CSF RT-QuIC showed positive α-synuclein seeding activity in 96% DLB and 15% AD patients with no differences in plasma biomarker levels in those stratified by RT-QuIC result. In a single-center clinical cohort, we confirm the high diagnostic value of plasma p-tau181 for distinguishing FTD from AD and plasma NfL for discriminating degenerative dementias from HC. Plasma GFAP alone differentiates AD from FTD and neurodegenerative dementias from HC but with lower accuracy than p-tau181 and NfL. In CBS and DLB, plasma p-tau181 and GFAP levels are significantly influenced by beta-amyloid pathology.
Sections du résumé
BACKGROUND
Increasing evidence supports the use of plasma biomarkers of neurodegeneration and neuroinflammation to screen and diagnose patients with dementia. However, confirmatory studies are required to demonstrate their usefulness in the clinical setting.
METHODS
We evaluated plasma and cerebrospinal fluid (CSF) samples from consecutive patients with frontotemporal dementia (FTD) (n = 59), progressive supranuclear palsy (PSP) (n = 31), corticobasal syndrome (CBS) (n = 29), dementia with Lewy bodies (DLB) (n = 49), Alzheimer disease (AD) (n = 97), and suspected non-AD physiopathology (n = 51), as well as plasma samples from 60 healthy controls (HC). We measured neurofilament light chain (NfL), phospho-tau181 (p-tau181), and glial fibrillary acid protein (GFAP) using Simoa (all plasma biomarkers and CSF GFAP), CLEIA (CSF p-tau181), and ELISA (CSF NfL) assays. Additionally, we stratified patients according to the A/T/N classification scheme and the CSF α-synuclein real-time quaking-induced conversion assay (RT-QuIC) results.
RESULTS
We found good correlations between CSF and plasma biomarkers for NfL (rho = 0.668, p < 0.001) and p-tau181 (rho = 0.619, p < 0.001). Plasma NfL was significantly higher in disease groups than in HC and showed a greater increase in FTD than in AD [44.9 (28.1-68.6) vs. 21.9 (17.0-27.9) pg/ml, p < 0.001]. Conversely, plasma p-tau181 and GFAP levels were significantly higher in AD than in FTD [3.2 (2.4-4.3) vs. 1.1 (0.7-1.6) pg/ml, p < 0.001; 404.7 (279.7-503.0) vs. 198.2 (143.9-316.8) pg/ml, p < 0.001]. GFAP also allowed discriminating disease groups from HC. In the distinction between FTD and AD, plasma p-tau181 showed better accuracy (AUC 0.964) than NfL (AUC 0.791) and GFAP (AUC 0.818). In DLB and CBS, CSF amyloid positive (A+) subjects had higher plasma p-tau181 and GFAP levels than A- individuals. CSF RT-QuIC showed positive α-synuclein seeding activity in 96% DLB and 15% AD patients with no differences in plasma biomarker levels in those stratified by RT-QuIC result.
CONCLUSIONS
In a single-center clinical cohort, we confirm the high diagnostic value of plasma p-tau181 for distinguishing FTD from AD and plasma NfL for discriminating degenerative dementias from HC. Plasma GFAP alone differentiates AD from FTD and neurodegenerative dementias from HC but with lower accuracy than p-tau181 and NfL. In CBS and DLB, plasma p-tau181 and GFAP levels are significantly influenced by beta-amyloid pathology.
Identifiants
pubmed: 36221099
doi: 10.1186/s13195-022-01093-6
pii: 10.1186/s13195-022-01093-6
pmc: PMC9555092
doi:
Substances chimiques
Amyloid beta-Peptides
0
Biomarkers
0
GFAP protein, human
0
Glial Fibrillary Acidic Protein
0
alpha-Synuclein
0
tau Proteins
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
153Informations de copyright
© 2022. The Author(s).
Références
JAMA Neurol. 2019 Jul 1;76(7):791-799
pubmed: 31009028
Neurology. 2013 Jan 29;80(5):496-503
pubmed: 23359374
Transl Neurodegener. 2021 Dec 10;10(1):50
pubmed: 34893073
J Alzheimers Dis. 2020;78(1):265-276
pubmed: 32986672
J Psychiatr Res. 2019 Jun;113:137-140
pubmed: 30953863
J Neurol Neurosurg Psychiatry. 2020 Mar;91(3):263-270
pubmed: 31937580
J Neurol Neurosurg Psychiatry. 2021 Dec;92(12):1305-1312
pubmed: 34187866
Alzheimers Dement. 2011 May;7(3):263-9
pubmed: 21514250
Neurology. 2017 Jul 4;89(1):88-100
pubmed: 28592453
Alzheimers Res Ther. 2020 Sep 28;12(1):118
pubmed: 32988409
Mov Disord. 2017 Jun;32(6):853-864
pubmed: 28467028
Acta Neuropathol. 2021 May;141(5):709-724
pubmed: 33585983
Nat Med. 2021 Jun;27(6):954-963
pubmed: 34083813
JAMA Neurol. 2021 Nov 1;78(11):1375-1382
pubmed: 34542571
Alzheimers Dement (Amst). 2019 Nov 04;11:730-743
pubmed: 31909174
Alzheimers Res Ther. 2021 Mar 27;13(1):68
pubmed: 33773595
Acta Neuropathol. 2015 May;129(5):729-48
pubmed: 25758940
Neurology. 2018 Oct 9;91(15):e1390-e1401
pubmed: 30209235
J Alzheimers Dis. 2018;66(2):551-563
pubmed: 30320576
Brain. 2011 Sep;134(Pt 9):2456-77
pubmed: 21810890
Amyotroph Lateral Scler Frontotemporal Degener. 2017 May;18(3-4):153-174
pubmed: 28054827
JAMA. 2020 Aug 25;324(8):772-781
pubmed: 32722745
Neurobiol Aging. 2018 Jun;66:180.e23-180.e31
pubmed: 29525180
Acta Neuropathol. 2020 Sep;140(3):267-278
pubmed: 32720099
Mov Disord. 2009 Aug 15;24(11):1593-9
pubmed: 19533751
Brain. 2021 Dec 16;144(11):3505-3516
pubmed: 34259835
Neurology. 2022 Mar 29;98(13):e1315-e1326
pubmed: 35110378
J Alzheimers Dis. 2020;77(3):1129-1141
pubmed: 32804092
JAMA Neurol. 2021 Dec 1;78(12):1471-1483
pubmed: 34661615
Nat Med. 2020 Mar;26(3):387-397
pubmed: 32123386
Lancet Neurol. 2014 Jun;13(6):614-29
pubmed: 24849862
Neurology. 2011 Mar 15;76(11):1006-14
pubmed: 21325651
Mov Disord. 2021 Mar;36(3):767-771
pubmed: 33285015
Neurology. 2020 Apr 28;94(17):743-755
pubmed: 32241955
Neurology. 2021 Aug 31;97(9):e930-e940
pubmed: 34210822
Alzheimers Dement. 2021 Jul;17(7):1145-1156
pubmed: 33491853
Alzheimers Res Ther. 2019 Dec 31;12(1):2
pubmed: 31892365
J Neurol Neurosurg Psychiatry. 2022 Jun;93(6):651-658
pubmed: 35078917
J Neuropathol Exp Neurol. 2013 Dec;72(12):1203-12
pubmed: 24226269
Alzheimer Dis Assoc Disord. 2002 Oct-Dec;16(4):203-12
pubmed: 12468894
Alzheimers Dement. 2018 Aug;14(8):989-997
pubmed: 29626426
Dement Geriatr Cogn Disord. 2008;26(4):343-50
pubmed: 18849605
Nat Commun. 2021 Jun 7;12(1):3400
pubmed: 34099648
Nat Med. 2020 Mar;26(3):379-386
pubmed: 32123385
JAMA Neurol. 2022 Jan 1;79(1):32-37
pubmed: 34807233
Acta Neuropathol. 2020 Jul;140(1):49-62
pubmed: 32342188
J Alzheimers Dis. 2019;67(2):481-488
pubmed: 30594925
J Neurol. 2020 Jan;267(1):162-167
pubmed: 31595378
Neurol Clin Pract. 2014 Aug;4(4):304-312
pubmed: 25279254
Alzheimers Dement. 2020 Apr;16(4):681-695
pubmed: 31879236
JAMA Neurol. 2019 Sep 01;76(9):1060-1069
pubmed: 31233127
NPJ Parkinsons Dis. 2021 Oct 11;7(1):93
pubmed: 34635674
Ann Clin Transl Neurol. 2018 Dec 14;6(2):263-273
pubmed: 30847359
J Neurol. 2017 Jul;264(7):1426-1433
pubmed: 28620717
Nat Rev Neurol. 2020 May;16(5):265-284
pubmed: 32322100